Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation

E-ISSN： 1875-6190|16|3|297-307

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.16, Iss.3, 2018-03, pp. : 297-307

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the Glutamatergic System to Treat Major Depressive Disorder: Rationale and Progress to Date

By Mathews Daniel C.

Drugs, Vol. 72, Iss. 10, 2012-07 ,pp. : 1313-1333

Adis International

Access to resources Recommend Favorite

Vilazodone: In Major Depressive Disorder

By Frampton James E.

CNS Drugs, Vol. 25, Iss. 7, 2011-07 ,pp. : 615-627

Adis International

Access to resources Recommend Favorite

Aripiprazole: In Major Depressive Disorder

By Weber Juliane Lyseng-Williamson Katherine A. Scott Lesley J.

CNS Drugs, Vol. 22, Iss. 10, 2008-01 ,pp. : 807-813

Adis International

Access to resources Recommend Favorite

Agomelatine for the treatment of major depressive disorder

By Carney Regina M Shelton Richard C

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 15, 2011-10 ,pp. : 2411-2419

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for major depressive disorder

By Kennedy Sidney H Rizvi Sakina J

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 3, 2009-09 ,pp. : 439-453

Informa Healthcare

Access to resources Recommend Favorite